InDevR Unveils Latest Version of Influenza Titer on Chip Product
BOULDER, CO: InDevR, a developer of advanced life science instrumentation and assays for analysis of viruses and other microorganisms has come up with VaxArray Influenza potency assay, a new version of its Influenza Titer on Chip or Flu-ToC product.
The new product released by the company is an immunoassay for hemagglutinin (HA) that uses antibodies involving subtype-specific, broadly reactive monoclonal rupture antibodies. The product offers results in just two hours. The flu researches and vaccine producers involved in vaccine research can now get all the information related to flu vaccine. Besides this, they can also gather information regarding samples of crude extracts through purification and concentration steps.
The improvements of the product includes longer reagent shelf-life, a semi-automation protocol for increased ease of use, less hands-on time, higher throughput and reduced assay time. In addition, VaxArray offers a streamlined automated data analysis package.
For influenza vaccines, typically HA quantification is performed using the single radial immunodiffusion assay (SRID). It is reliant on seasonal reference antisera and antigens as well as gels that must be prepared in-house. Subsequently, analysis can be inconsistent between laboratories and scientists. SRID is also a singleplex method known to have limited dynamic range. The VaxArray Influenza potency assay has been recognized by the US Department of Health and Human Services as a promising alternative to SRID.
"Time to market in the vaccine industry is critical. With VaxArray customers save valuable time with an off-the-shelf potency assay that allows them to assess HA concentration and stability within hours rather than days, even during the early stages of development," says Kathy Rowlen, Chief Executive Officer, InDevR. "We have re-branded Flu-ToC to better reflect the platform flexibility. While VaxArray Influenza is the first potency assay we've launched, the technology will be useful for other vaccines as well. Animal vaccines and vaccines against potential pandemic influenza viruses represent another great market opportunity for this product and we intend to pursue those applications next."
By James Seevers, CIO & GM, Toyoda Gosei
By Bill Krivoshik, SVP & CIO, Time Warner Inc.
By Gregory Morrison, SVP & CIO, Cox Enterprises
By Alberto Ruocco, CIO, American Electric Power
By Bruce. D. Smith, SVP & CIO, Information Systems, Advocate...
By Adrian Mebane, VP-Global Ethics & Compliance, The Hershey...
By Graham Welch, Director-Cisco Security, Cisco
By Michael Watkins, Senior Product Director, Global Knowledge
By Bernd Schlotter, President of Services, Unify
By Patrick Hale, CIO, VITAS Healthcare
By Steve Bein, VP-GIS, Michael Baker International
By Jason Alan Snyder, CTO, Momentum Worldwide
By Mike Morris, CIO, Legends
By Louis Carr, Jr., CIO, Clark County
By Bill Dow, SVP and General Manager of Business Solutions,...
By Jim Whitehurst, CEO, Red Hat
By Darren Cockrel, CIO, Coyote Logistics, a UPS Company...
By Nathan Johnson, SVP and CIO, Werner Enterprises [NASDAQ:...
By David Tamayo, CIO, DCS Corporation
By Neil Hampshire, CIO, ModusLink Global Solutions, Inc....